Neurology, Vol 44, Issue 1 16-20, Copyright © 1994 by American Academy of Neurology

ARTICLES

The impact of blinding on the results of a randomized, placebo- controlled multiple sclerosis clinical trial

JH Noseworthy, GC Ebers, MK Vandervoort, RE Farquhar, E Yetisir and R Roberts
Department of Neurology, Mayo Clinic and Foundation, Rochester, MN 55905.

In the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: i.v. cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to placebo (group III: sham plasma exchange and placebo medications) using the blinded, evaluating neurologists' assessments of disease course (primary analysis). All patients were examined by both a blinded and an unblinded neurologist at each assessment in this trial. We compared the blinded and unblinded neurologists' judgment of treatment response and analyzed the clinical behavior of patients who correctly guessed their treatment. The unblinded (but not the blinded) neurologists' scores demonstrated an apparent treatment benefit at 6, 12, and 24 months for the group II patients (not group I or placebo; p < 0.05, two-tailed). There were no significant differences in the time to treatment failure or in the proportions of patients improved, stable, or worse between the group II and group III patients who correctly guessed their treatment assignments and those who did not. Physician blinding prevented an erroneous conclusion about treatment efficacy (false positive, type 1 error).

This article has been cited by other articles:

				S C Lewis and C P Warlow How to spot bias and other potential problems in randomised controlled trials J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 181 - 187. [Full Text] [PDF]

				I. Boutron, F. Tubach, B. Giraudeau, and P. Ravaud Methodological Differences in Clinical Trials Evaluating Nonpharmacological and Pharmacological Treatments of Hip and Knee Osteoarthritis JAMA, August 27, 2003; 290(8): 1062 - 1070. [Abstract] [Full Text] [PDF]

				H. L. Tremlett and J. Oger Interrupted therapy: Stopping and switching of the {beta}-interferons prescribed for MS Neurology, August 26, 2003; 61(4): 551 - 554. [Abstract] [Full Text] [PDF]

				D. G. Altman, K. F. Schulz, D. Moher, M. Egger, F. Davidoff, D. Elbourne, P. C. Gotzsche, and T. Lang The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration Ann Intern Med, April 17, 2001; 134(8): 663 - 694. [Abstract] [Full Text] [PDF]

				A E Powell, H T O Davies, and R G Thomson Using routine comparative data to assess the quality of health care: understanding and avoiding common pitfalls Qual. Saf. Health Care, April 1, 2003; 12(2): 122 - 128. [Abstract] [Full Text] [PDF]

				P. Juni, A. Witschi, R. Bloch, and M. Egger The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis JAMA, September 15, 1999; 282(11): 1054 - 1060. [Abstract] [Full Text] [PDF]

				C. L M Sudlow and C. E Counsell Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis BMJ, February 15, 2003; 326(7385): 388 - 392. [Full Text] [PDF]

				P J Devereaux, M. Bhandari, V. M Montori, B. J Manns, W. A Ghali, and G. H Guyatt Double blind, you have been voted off the island! Evid. Based Ment. Health, May 1, 2002; 5(2): 36 - 37. [Full Text] [PDF]

				P. Devereaux, M. Bhandari, V. M Montori, B. J Manns, W. A Ghali, and G. H Guyatt "Double blind, you are the weakest link -- goodbye!" Evid. Based Nurs., April 1, 2002; 5(2): 36 - 37. [Full Text] [PDF]

				P J Devereaux, M. Bhandari, V. M Montori, B. J Manns, W. A Ghali, and G. H Guyatt ""Double blind, you are the weakest link -- goodbye!"" Evid. Based Med., January 1, 2002; 7(1): 4 - 5. [Full Text] [PDF]

				G C Ebers NATURAL HISTORY OF MULTIPLE SCLEROSIS J. Neurol. Neurosurg. Psychiatry, December 1, 2001; 71(suppl_2): ii16 - ii19. [Full Text] [PDF]

				P. Juni, D. G Altman, and M. Egger Systematic reviews in health care: Assessing the quality of controlled clinical trials BMJ, July 7, 2001; 323(7303): 42 - 46. [Full Text] [PDF]

				C. Parker and M. Dewey Assessing research outcomes by postal questionnaire with telephone follow-up Int. J. Epidemiol., December 1, 2000; 29(6): 1065 - 1069. [Abstract] [Full Text]

				C. G. Goetz, S. Leurgans, R. Raman, and G. T. Stebbins Objective changes in motor function during placebo treatment in PD Neurology, February 8, 2000; 54(3): 710 - 710. [Abstract] [Full Text] [PDF]

				R. Keatinge and R. Parry Protection afforded by cycle helmets BMJ, November 26, 1994; 309(6966): 1441a - 1441. [Full Text]

				R. Keatinge Carotid endarterectomy BMJ, April 29, 1995; 310(6987): 1135 - 1135. [Full Text]

				D. A. Cottrell, M. Kremenchutzky, G. P. A. Rice, W. J. Koopman, W. Hader, J. Baskerville, and G. C. Ebers The natural history of multiple sclerosis:a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis Brain, April 1, 1999; 122(4): 625 - 639. [Abstract] [Full Text]

				L. Roberts and C. Counsell Assessment of Clinical Outcomes in Acute Stroke Trials Stroke, May 1, 1998; 29(5): 986 - 991. [Abstract] [Full Text] [PDF]

				P M Rothwell, Z McDowell, C K Wong, and P J Dorman Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis BMJ, May 31, 1997; 314(7094): 1580 - 1580. [Abstract] [Full Text]